We generally tend to focus on different organs, but we forget that all the organs are internally connected. In this article, ...

Weight loss is a key effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), but these drugs may also provide liver ...

The tool reduces pathologist variability in liver biopsy assessment during trials of treatments for metabolic ...

EMA’s human medicines committee qualifies first AI tool to diagnose inflammatory liver disease in biopsy samples: Amsterdam, The Netherlands Saturday, March 22, 2025, 16:00 Hrs ...

PathAI, a global leader in AI-powered pathology, today announced that the European Medicines Agency (EMA) Committee for ...

Non-alcoholic fatty liver disease (NAFLD) represents the most common liver disease worldwide affecting approximatively 20–30% ...

While the myelofibrosis drug landscape has become more crowded since Syntara (then Pharmaxis) decided to focus on that ...

The liver is the body’s chemical factory, where most metabolic processes take place. It processes everything you eat and drink, converting them into energy and essential nutrients. Additionally, the ...

Discover preclinical studies that indicate that empagliflozin reduces liver fat, improves liver function markers, and decreases inflammation.

Medically reviewed by Qin Rao, MD Metabolic dysfunction-associated steatohepatitis (MASH)—previously known as nonalcoholic steatohepatitis (NASH)—occurs when fat buildup in the liver causes liver ...

Left untreated, NAFLD can progress to non-alcoholic steatohepatitis (NASH), a severe ... improvement in fatty liver stage. Key findings include: - Liver Fibrosis Reversal: 83.3% of participants ...